Melioidosis: Evolving concepts in epidemiology, pathogenesis, and treatment

Seminars in Respiratory and Critical Care Medicine

Volumn 36, Issue 1, 2015, Pages 111-125

  Currie, Bart J ^a  

^a ROYAL DARWIN HOSPITAL   (Australia)

Author keywords

antimicrobial resistance; biothreat; Burkholderia pseudomallei; melioidosis; sepsis; therapy

Indexed keywords

AMOXICILLIN PLUS CLAVULANIC ACID; ANTIINFECTIVE AGENT; CEFTAZIDIME; DRUG THERAPY; FOLIC ACID; MEROPENEM; SULFAMETHOXAZOLE; TRIMETHOPRIM; VIRULENCE FACTOR;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC THERAPY; ARTICLE; BACTEREMIA; BACTERIAL ARTHRITIS; BACTERIAL LOAD; BACTERIAL VIRULENCE; BURKHOLDERIA PSEUDOMALLEI; CENTRAL NERVOUS SYSTEM INFECTION; CLINICAL FEATURE; DRUG THERAPY; EPIDEMIOLOGY; ERADICATION THERAPY; ETIOLOGY; GLANDERS; HEALTH; HUMAN; INFECTION RISK; INHALATION; INOCULATION; INTENSIVE CARE; LABORATORY DIAGNOSIS; MELIOIDOSIS; NONHUMAN; OSTEOMYELITIS; PATHOGENICITY; PNEUMONIA; PRIORITY JOURNAL; SEROCONVERSION; SKIN ABSCESS; TREATMENT DURATION;

ANTI-BACTERIAL AGENTS; BURKHOLDERIA PSEUDOMALLEI; DRUG RESISTANCE, BACTERIAL; DRUG THERAPY; EPIDEMIOLOGY; ETIOLOGY; GLOBAL HEALTH; HUMANS; MELIOIDOSIS; PATHOGENICITY; THERAPEUTIC USE;

EID: 84964266964     PISSN: 10693424     EISSN: 10989048     Source Type: Journal    
DOI: 10.1055/s-0034-1398389     Document Type: Article

References (164)

1. Wiersinga W. J.; Currie B. J.; Peacock S. J. Melioidosis. N Engl J Med: 2012; 367 11 1035 1044
2. White N. J. Melioidosis. Lancet: 2003; 361 9370 1715 1722
3. Cheng A. C.; Currie B. J. Melioidosis: epidemiology, pathophysiology, and management. Clin Microbiol Rev: 2005; 18 2 383 416
4. Leelarasamee A.; Bovornkitti S. Melioidosis: review and update. Rev Infect Dis: 1989; 11 3 413 425
5. Vandamme P.; Dawyndt P. Classification and identification of the Burkholderia cepacia complex: Past, present and future. Syst Appl Microbiol: 2011; 34 2 87 95
6. Compant S.; Nowak J.; Coenye T.; Clément C.; Ait Barka E. Diversity and occurrence of Burkholderia spp. in the natural environment. FEMS Microbiol Rev: 2008; 32 4 607 626
7. Gee J. E.; Glass M. B.; Novak R. T.; et al. Recovery of a Burkholderia thailandensis-like isolate from an Australian water source. BMC Microbiol: 2008; 8 54
8. Liu X.; Biswas S.; Berg M. G.; et al. Genomics-guided discovery of thailanstatins A, B, and C As pre-mRNA splicing inhibitors and antiproliferative agents from Burkholderia thailandensis MSMB43. J Nat Prod: 2013; 76 4 685 693
9. Coenye T.; Spilker T.; Van Schoor A.; LiPuma J. J.; Vandamme P. Recovery of Burkholderia cenocepacia strain PHDC from cystic fibrosis patients in Europe. Thorax: 2004; 59 11 952 954
10. Whitmore A.; Krishnaswami C. S. An account of the discovery of a hitherto underscribed infective disease occurring among the population of Rangoon. Ind Med Gaz: 1912; 47 262 267
11. Stanton A. T.; Fletcher W. Melioidosis: a new disease of the tropics. Trans Fourth Congr Far East Assoc Trop Med: 1921; 2 196 198
12. Godoy D.; Randle G.; Simpson A. J.; et al. Multilocus sequence typing and evolutionary relationships among the causative agents of melioidosis and glanders, Burkholderia pseudomallei and Burkholderia mallei. J Clin Microbiol: 2003; 41 5 2068 2079
13. Holden M. T.; Titball R. W.; Peacock S. J.; et al. Genomic plasticity of the causative agent of melioidosis, Burkholderia pseudomallei. Proc Natl Acad Sci U S A: 2004; 101 39 14240 14245
14. Nierman W. C.; DeShazer D.; Kim H. S.; et al. Structural flexibility in the Burkholderia mallei genome. Proc Natl Acad Sci U S A: 2004; 101 39 14246 14251
15. Deitchman S.; Sokas R. Glanders in a military research microbiologist. N Engl J Med: 2001; 345 22 1644
16. Currie B. J.; Ward L.; Cheng A. C. The epidemiology and clinical spectrum of melioidosis: 540 cases from the 20-year Darwin prospective study. PLoS Negl Trop Dis: 2010; 4 11 e900
17. Wheelis M. First shots fired in biological warfare. Nature: 1998; 395 6699 213
18. Butler D. Viral research faces clampdown. Nature: 2012; 490 7421 456
19. Dance D. A. Melioidosis: the tip of the iceberg? Clin Microbiol Rev: 1991; 4 1 52 60
20. Leelarasamee A. Melioidosis in Southeast Asia. Acta Trop: 2000; 74 2-3 129 132
21. Limmathurotsakul D.; Wongratanacheewin S.; Teerawattanasook N.; et al. Increasing incidence of human melioidosis in Northeast Thailand. Am J Trop Med Hyg: 2010; 82 6 1113 1117
22. Chaowagul W.; White N. J.; Dance D. A.; et al. Melioidosis: a major cause of community-acquired septicemia in northeastern Thailand. J Infect Dis: 1989; 159 5 890 899
23. Parameswaran U.; Baird R. W.; Ward L. M.; Currie B. J. Melioidosis at Royal Darwin Hospital in the big 2009-2010 wet season: comparison with the preceding 20 years. Med J Aust: 2012; 196 5 345 348
24. Currie B. J.; Dance D. A.; Cheng A. C. The global distribution of Burkholderia pseudomallei and melioidosis: an update. Trans R Soc Trop Med Hyg: 2008; 102 01 S1 S4
25. Inglis T. J.; Rolim D. B.; Sousa AdeQ. Melioidosis in the Americas. Am J Trop Med Hyg: 2006; 75 5 947 954
26. Doker T. J.; Sharp T. M.; Rivera-Garcia B.; et al. Contact Investigation of Melioidosis Cases Reveals Regional Endemicity in Puerto Rico. Clin Infect Dis: 2014
27. Garin B.; Djaomazala I.; Dubois-Cauwelaert N.; et al. Mahafaly. Autochthonous melioidosis in humans, Madagascar, 2012 and 2013. Emerg Infect Dis: 2014; 20 10 1739 1741
28. Katangwe T.; Purcell J.; Bar-Zeev N.; et al. Human melioidosis, Malawi, 2011. Emerg Infect Dis: 2013; 19 6 981 984
29. Kaestli M.; Schmid M.; Mayo M.; et al. Out of the ground: aerial and exotic habitats of the melioidosis bacterium Burkholderia pseudomallei in grasses in Australia. Environ Microbiol: 2012; 14 8 2058 2070
30. Pearson T.; Giffard P.; Beckstrom-Sternberg S.; et al. Phylogeographic reconstruction of a bacterial species with high levels of lateral gene transfer. BMC Biol: 2009; 7 78
31. Gee J. E.; Allender C. J.; Tuanyok A.; Elrod M. G.; Hoffmaster A. R. Burkholderia pseudomallei type G in Western Hemisphere. Emerg Infect Dis: 2014; 20 4 682 684
32. Bodilsen J.; Vammen S.; Fuursted K.; Hjort U. Mycotic aneurysm caused by Burkholderia pseudomallei in a previously healthy returning traveller. BMJ Case Rep: 2014; Sep 22;2014. pii: bcr2013202824. doi: 10.1136/bcr-2013-202824
33. Currie B. J. Melioidosis: an important cause of pneumonia in residents of and travellers returned from endemic regions. Eur Respir J: 2003; 22 3 542 550
34. Doker T. J.; Quinn C. L.; Salehi E. D.; et al. Melioidosis Investigation Team. Fatal Burkholderia pseudomallei infection initially reported as a Bacillus species, Ohio, 2013. Am J Trop Med Hyg: 2014; 91 4 743 746
35. Stewart T.; Engelthaler D. M.; Blaney D. D.; et al. Epidemiology and investigation of melioidosis, Southern Arizona. Emerg Infect Dis: 2011; 17 7 1286 1288
36. Engelthaler D. M.; Bowers J.; Schupp J. A.; et al. Molecular investigations of a locally acquired case of melioidosis in Southern AZ, USA. PLoS Negl Trop Dis: 2011; 5 10 e1347
37. Limmathurotsakul D.; Kanoksil M.; Wuthiekanun V.; et al. Activities of daily living associated with acquisition of melioidosis in northeast Thailand: a matched case-control study. PLoS Negl Trop Dis: 2013; 7 2 e2072
38. Inglis T. J.; Garrow S. C.; Henderson M.; et al. Burkholderia pseudomallei traced to water treatment plant in Australia. Emerg Infect Dis: 2000; 6 1 56 59
39. Currie B. J.; Mayo M.; Anstey N. M.; Donohoe P.; Haase A.; Kemp D. J. A cluster of melioidosis cases from an endemic region is clonal and is linked to the water supply using molecular typing of Burkholderia pseudomallei isolates. Am J Trop Med Hyg: 2001; 65 3 177 179
40. Ralph A.; McBride J.; Currie B. J. Transmission of Burkholderia pseudomallei via breast milk in northern Australia. Pediatr Infect Dis J: 2004; 23 12 1169 1171
41. Thatrimontrichai A.; Maneenil G. Neonatal melioidosis: systematic review of the literature. Pediatr Infect Dis J: 2012; 31 11 1195 1197
42. Choy J. L.; Mayo M.; Janmaat A.; Currie B. J. Animal melioidosis in Australia. Acta Trop: 2000; 74 2-3 153 158
43. Cheng A. C.; Jacups S. P.; Gal D.; Mayo M.; Currie B. J. Extreme weather events and environmental contamination are associated with case-clusters of melioidosis in the Northern Territory of Australia. Int J Epidemiol: 2006; 35 2 323 329
44. Lo T. J.; Ang L. W.; James L.; Goh K. T. Melioidosis in a tropical city state, Singapore. Emerg Infect Dis: 2009; 15 10 1645 1647
45. Currie B. J.; Jacups S. P. Intensity of rainfall and severity of melioidosis, Australia. Emerg Infect Dis: 2003; 9 12 1538 1542
46. Ko W. C.; Cheung B. M.; Tang H. J.; et al. Melioidosis outbreak after typhoon, southern Taiwan. Emerg Infect Dis: 2007; 13 6 896 898
47. Chen Y. L.; Yen Y. C.; Yang C. Y.; et al. The concentrations of ambient Burkholderia pseudomallei during typhoon season in endemic area of melioidosis in Taiwan. PLoS Negl Trop Dis: 2014; 8 5 e2877
48. Currie B. J.; Fisher D. A.; Howard D. M.; et al. The epidemiology of melioidosis in Australia and Papua New Guinea. Acta Trop: 2000; 74 2-3 121 127
49. Allworth A. M. Tsunami lung: a necrotising pneumonia in survivors of the Asian tsunami. Med J Aust: 2005; 182 7 364
50. Athan E.; Allworth A. M.; Engler C.; Bastian I.; Cheng A. C. Melioidosis in tsunami survivors. Emerg Infect Dis: 2005; 11 10 1638 1639
51. Chierakul W.; Winothai W.; Wattanawaitunechai C.; et al. Melioidosis in 6 tsunami survivors in southern Thailand. Clin Infect Dis: 2005; 41 7 982 990
52. Howe C.; Sampath A.; Spotnitz M. The pseudomallei group: a review. J Infect Dis: 1971; 124 6 598 606
53. Amadasi S.; Dal Zoppo S.; Bonomini A.; et al. A Case of Melioidosis Probably Acquired by Inhalation of Dusts During a Helicopter Flight in a Healthy Traveler Returning From Singapore. J Travel Med: 2014
54. Jeddeloh J. A.; Fritz D. L.; Waag D. M.; Hartings J. M.; Andrews G. P. Biodefense-driven murine model of pneumonic melioidosis. Infect Immun: 2003; 71 1 584 587
55. West T. E.; Myers N. D.; Liggitt H. D.; Skerrett S. J. Murine pulmonary infection and inflammation induced by inhalation of Burkholderia pseudomallei. Int J Exp Pathol: 2012; 93 6 421 428
56. Nelson M.; Dean R. E.; Salguero F. J.; et al. Development of an acute model of inhalational melioidosis in the common marmoset (Callithrix jacchus). Int J Exp Pathol: 2011; 92 6 428 435
57. Titball R. W.; Russell P.; Cuccui J.; et al. Burkholderia pseudomallei: animal models of infection. Trans R Soc Trop Med Hyg: 2008; 102 01 S111 S116
58. Cheng A. C.; Currie B. J.; Dance D. A.; et al. Clinical definitions of melioidosis. Am J Trop Med Hyg: 2013; 88 3 411 413
59. Cheng A. C.; Wuthiekanun V.; Limmathurotsakul D.; Chierakul W.; Peacock S. J. Intensity of exposure and incidence of melioidosis in Thai children. Trans R Soc Trop Med Hyg: 2008; 102 01 S37 S39
60. Wuthiekanun V.; Chierakul W.; Langa S.; et al. Development of antibodies to Burkholderia pseudomallei during childhood in melioidosis-endemic northeast Thailand. Am J Trop Med Hyg: 2006; 74 6 1074 1075
61. James G. L.; Delaney B.; Ward L.; Freeman K.; Mayo M.; Currie B. J. Surprisingly low seroprevalence of Burkholderia pseudomallei in exposed healthy adults in the Darwin region of tropical Australia where melioidosis is highly endemic. Clin Vaccine Immunol: 2013; 20 5 759 760
62. Ashdown L. R.; Guard R. W. The prevalence of human melioidosis in Northern Queensland. Am J Trop Med Hyg: 1984; 33 3 474 478
63. Clayton A. J.; Lisella R. S.; Martin D. G. Melioidosis: a serological survey in military personnel. Mil Med: 1973; 138 1 24 26
64. Currie B. J.; Fisher D. A.; Anstey N. M.; Jacups S. P. Melioidosis: acute and chronic disease, relapse and re-activation. Trans R Soc Trop Med Hyg: 2000; 94 3 301 304
65. Suputtamongkol Y.; Hall A. J.; Dance D. A.; et al. The epidemiology of melioidosis in Ubon Ratchatani, northeast Thailand. Int J Epidemiol: 1994; 23 5 1082 1090
66. Ngauy V.; Lemeshev Y.; Sadkowski L.; Crawford G. Cutaneous melioidosis in a man who was taken as a prisoner of war by the Japanese during World War II. J Clin Microbiol: 2005; 43 2 970 972
67. Kingston C. W. Chronic or latent melioidosis. Med J Aust: 1971; 2 12 618 621
68. McLeod C.; Morris P. S.; Bauert P. A.; et al. Clinical presentation and medical management of melioidosis in children: a 24-year prospective study in the Northern Territory of Australia and review of the literature. Clin Infect Dis: 2014
69. Suputtamongkol Y.; Chaowagul W.; Chetchotisakd P.; et al. Risk factors for melioidosis and bacteremic melioidosis. Clin Infect Dis: 1999; 29 2 408 413
70. Limmathurotsakul D.; Chaowagul W.; Chierakul W.; et al. Risk factors for recurrent melioidosis in northeast Thailand. Clin Infect Dis: 2006; 43 8 979 986
71. Currie B. J.; Fisher D. A.; Howard D. M.; et al. Endemic melioidosis in tropical northern Australia: a 10-year prospective study and review of the literature. Clin Infect Dis: 2000; 31 4 981 986
72. Easton A.; Haque A.; Chu K.; Lukaszewski R.; Bancroft G. J. A critical role for neutrophils in resistance to experimental infection with Burkholderia pseudomallei. J Infect Dis: 2007; 195 1 99 107
73. Wiersinga W. J.; van der Poll T.; White N. J.; Day N. P.; Peacock S. J. Melioidosis: insights into the pathogenicity of Burkholderia pseudomallei. Nat Rev Microbiol: 2006; 4 4 272 282
74. Wiersinga W. J.; Wieland C. W.; Dessing M. C.; et al. Toll-like receptor 2 impairs host defense in gram-negative sepsis caused by Burkholderia pseudomallei (Melioidosis). PLoS Med: 2007; 4 7 e248
75. West T. E.; Myers N. D.; Chantratita N.; et al. NLRC4 and TLR5 each contribute to host defense in respiratory melioidosis. PLoS Negl Trop Dis: 2014; 8 9 e3178
76. Myers N. D.; Chantratita N.; Berrington W. R.; et al. The role of NOD2 in murine and human melioidosis. J Immunol: 2014; 192 1 300 307
77. Nuntayanuwat S.; Dharakul T.; Chaowagul W.; Songsivilai S. Polymorphism in the promoter region of tumor necrosis factor-alpha gene is associated with severe meliodosis. Hum Immunol: 1999; 60 10 979 983
78. Chantratita N.; Tandhavanant S.; Myers N. D.; et al. Common TLR1 genetic variation is not associated with death from melioidosis, a common cause of sepsis in rural Thailand. PLoS ONE: 2014; 9 1 e83285
79. Chantratita N.; Tandhavanant S.; Myers N. D.; et al. Screen of whole blood responses to flagellin identifies TLR5 variation associated with outcome in melioidosis. Genes Immun: 2014; 15 2 63 71
80. West T. E.; Chierakul W.; Chantratita N.; et al. Toll-like receptor 4 region genetic variants are associated with susceptibility to melioidosis. Genes Immun: 2012; 13 1 38 46
81. West T. E.; Chantratita N.; Chierakul W.; et al. Impaired TLR5 functionality is associated with survival in melioidosis. J Immunol: 2013; 190 7 3373 3379
82. Barnes J. L.; Warner J.; Melrose W.; et al. Adaptive immunity in melioidosis: a possible role for T cells in determining outcome of infection with Burkholderia pseudomallei. Clin Immunol: 2004; 113 1 22 28
83. Ketheesan N.; Barnes J. L.; Ulett G. C.; et al. Demonstration of a cell-mediated immune response in melioidosis. J Infect Dis: 2002; 186 2 286 289
84. Chierakul W.; Wuthiekanun V.; Chaowagul W.; et al. Short report: disease severity and outcome of melioidosis in HIV coinfected individuals. Am J Trop Med Hyg: 2005; 73 6 1165 1166
85. Sarovich D. S.; Ward L.; Price E. P.; et al. Recurrent melioidosis in the Darwin Prospective Melioidosis Study: improving therapies mean that relapse cases are now rare. J Clin Microbiol: 2014; 52 2 650 653
86. Tuanyok A.; Auerbach R. K.; Brettin T. S.; et al. A horizontal gene transfer event defines two distinct groups within Burkholderia pseudomallei that have dissimilar geographic distributions. J Bacteriol: 2007; 189 24 9044 9049
87. Tuanyok A.; Leadem B. R.; Auerbach R. K.; et al. Genomic islands from five strains of Burkholderia pseudomallei. BMC Genomics: 2008; 9 566
88. Reckseidler-Zenteno S. L.; DeVinney R.; Woods D. E. The capsular polysaccharide of Burkholderia pseudomallei contributes to survival in serum by reducing complement factor C3b deposition. Infect Immun: 2005; 73 2 1106 1115
89. DeShazer D.; Brett P. J.; Woods D. E. The type II O-antigenic polysaccharide moiety of Burkholderia pseudomallei lipopolysaccharide is required for serum resistance and virulence. Mol Microbiol: 1998; 30 5 1081 1100
90. Stevens M. P.; Wood M. W.; Taylor L. A.; et al. An Inv/Mxi-Spa-like type III protein secretion system in Burkholderia pseudomallei modulates intracellular behaviour of the pathogen. Mol Microbiol: 2002; 46 3 649 659
91. Burtnick M. N.; Brett P. J.; Harding S. V.; et al. The cluster 1 type VI secretion system is a major virulence determinant in Burkholderia pseudomallei. Infect Immun: 2011; 79 4 1512 1525
92. Ulrich R. L.; Deshazer D.; Brueggemann E. E.; Hines H. B.; Oyston P. C.; Jeddeloh J. A. Role of quorum sensing in the pathogenicity of Burkholderia pseudomallei. J Med Microbiol: 2004; 53 Pt 11 1053 1064
93. Cruz-Migoni A.; Hautbergue G. M.; Artymiuk P. J.; et al. A Burkholderia pseudomallei toxin inhibits helicase activity of translation factor eIF4A. Science: 2011; 334 6057 821 824
94. Chantratita N.; Tandhavanant S.; Wikraiphat C.; et al. Proteomic analysis of colony morphology variants of Burkholderia pseudomallei defines a role for the arginine deiminase system in bacterial survival. J Proteomics: 2012; 75 3 1031 1042
95. Chantratita N.; Wuthiekanun V.; Boonbumrung K.; et al. Biological relevance of colony morphology and phenotypic switching by Burkholderia pseudomallei. J Bacteriol: 2007; 189 3 807 817
96. Ulett G. C.; Currie B. J.; Clair T. W.; et al. Burkholderia pseudomallei virulence: definition, stability and association with clonality. Microbes Infect: 2001; 3 8 621 631
97. Sarovich D. S.; Price E. P.; Webb J. R.; et al. Variable virulence factors in Burkholderia pseudomallei (melioidosis) associated with human disease. PLoS ONE: 2014; 9 3 e91682
98. Achana V.; Silpapojakul K.; Thininta W.; Kalnaowakul S. Acute Pseudomonas pseudomallei pneumonia and septicemia following aspiration of contaminated water: a case report. Southeast Asian J Trop Med Public Health: 1985; 16 3 500 504
99. Lee N.; Wu J. L.; Lee C. H.; Tsai W. C. Pseudomonas pseudomallei infection from drowning: the first reported case in Taiwan. J Clin Microbiol: 1985; 22 3 352 354
100. Meumann E. M.; Cheng A. C.; Ward L.; Currie B. J. Clinical features and epidemiology of melioidosis pneumonia: results from a 21-year study and review of the literature. Clin Infect Dis: 2012; 54 3 362 369
101. Gibney K. B.; Cheng A. C.; Currie B. J. Cutaneous melioidosis in the tropical top end of Australia: a prospective study and review of the literature. Clin Infect Dis: 2008; 47 5 603 609
102. Dance D. A.; Davis T. M.; Wattanagoon Y.; et al. Acute suppurative parotitis caused by Pseudomonas pseudomallei in children. J Infect Dis: 1989; 159 4 654 660
103. Pagnarith Y.; Kumar V.; Thaipadungpanit J.; et al. Emergence of pediatric melioidosis in Siem Reap, Cambodia. Am J Trop Med Hyg: 2010; 82 6 1106 1112
104. Morse L. P.; Moller C. C.; Harvey E.; et al. Prostatic abscess due to Burkholderia pseudomallei: 81 cases from a 19-year prospective melioidosis study. J Urol: 2009; 182 2 542 547, discussion 547
105. Jabbar Z.; Currie B. J. Melioidosis and the kidney. Nephrology (Carlton): 2013; 18 3 169 175
106. Woods M. L. II, Currie B. J.; Howard D. M.; et al. Neurological melioidosis: seven cases from the Northern Territory of Australia. Clin Infect Dis: 1992; 15 1 163 169
107. Currie B. J.; Fisher D. A.; Howard D. M.; Burrow J. N. Neurological melioidosis. Acta Trop: 2000; 74 2-3 145 151
108. Koszyca B.; Currie B. J.; Blumbergs P. C. The neuropathology of melioidosis: two cases and a review of the literature. Clin Neuropathol: 2004; 23 5 195 203
109. Chadwick D. R.; Ang B.; Sitoh Y. Y.; Lee C. C. Cerebral melioidosis in Singapore: a review of five cases. Trans R Soc Trop Med Hyg: 2002; 96 1 72 76
110. Owen S. J.; Batzloff M.; Chehrehasa F.; et al. Nasal-associated lymphoid tissue and olfactory epithelium as portals of entry for Burkholderia pseudomallei in murine melioidosis. J Infect Dis: 2009; 199 12 1761 1770
111. St John J. A.; Ekberg J. A.; Dando S. J.; et al. Burkholderia pseudomallei penetrates the brain via destruction of the olfactory and trigeminal nerves: implications for the pathogenesis of neurological melioidosis. MBio: 2014; 5 2 e00025
112. Morse L. P.; Smith J.; Mehta J.; Ward L.; Cheng A. C.; Currie B. J. Osteomyelitis and septic arthritis from infection with Burkholderia pseudomallei: A 20-year prospective melioidosis study from northern Australia. J Orthop: 2013; 10 2 86 91
113. Cooper A.; Williams N. L.; Morris J. L.; Norton R. E.; Ketheesan N.; Schaeffer P. M. ELISA and immuno-polymerase chain reaction assays for the sensitive detection of melioidosis. Diagn Microbiol Infect Dis: 2013; 75 2 135 138
114. Cheng A. C.; O'brien M.; Freeman K.; Lum G.; Currie B. J. Indirect hemagglutination assay in patients with melioidosis in northern Australia. Am J Trop Med Hyg: 2006; 74 2 330 334
115. Lowe P.; Engler C.; Norton R. Comparison of automated and nonautomated systems for identification of Burkholderia pseudomallei. J Clin Microbiol: 2002; 40 12 4625 4627
116. Podin Y.; Kaestli M.; McMahon N.; et al. Reliability of automated biochemical identification of Burkholderia pseudomallei is regionally dependent. J Clin Microbiol: 2013; 51 9 3076 3078
117. Cunningham S. A.; Patel R. Importance of using Bruker's security-relevant library for Biotyper identification of Burkholderia pseudomallei, Brucella species, and Francisella tularensis. J Clin Microbiol: 2013; 51 5 1639 1640
118. Peacock S. J.; Chieng G.; Cheng A. C.; et al. Comparison of Ashdown's medium, Burkholderia cepacia medium, and Burkholderia pseudomallei selective agar for clinical isolation of Burkholderia pseudomallei. J Clin Microbiol: 2005; 43 10 5359 5361
119. Wuthiekanun V.; Dance D. A.; Wattanagoon Y.; Supputtamongkol Y.; Chaowagul W.; White N. J. The use of selective media for the isolation of Pseudomonas pseudomallei in clinical practice. J Med Microbiol: 1990; 33 2 121 126
120. Dance D. A.; Wuthiekanun V.; Naigowit P.; White N. J. Identification of Pseudomonas pseudomallei in clinical practice: use of simple screening tests and API 20NE. J Clin Pathol: 1989; 42 6 645 648
121. Novak R. T.; Glass M. B.; Gee J. E.; et al. Development and evaluation of a real-time PCR assay targeting the type III secretion system of Burkholderia pseudomallei. J Clin Microbiol: 2006; 44 1 85 90
122. Amornchai P.; Chierakul W.; Wuthiekanun V.; et al. Accuracy of Burkholderia pseudomallei identification using the API 20NE system and a latex agglutination test. J Clin Microbiol: 2007; 45 11 3774 3776
123. Chantratita N.; Tandhavanant S.; Wongsuvan G.; et al. Rapid detection of Burkholderia pseudomallei in blood cultures using a monoclonal antibody-based immunofluorescent assay. Am J Trop Med Hyg: 2013; 89 5 971 972
124. Kaestli M.; Richardson L. J.; Colman R. E.; et al. Comparison of TaqMan PCR assays for detection of the melioidosis agent Burkholderia pseudomallei in clinical specimens. J Clin Microbiol: 2012; 50 6 2059 2062
125. Meumann E. M.; Novak R. T.; Gal D.; et al. Clinical evaluation of a type III secretion system real-time PCR assay for diagnosing melioidosis. J Clin Microbiol: 2006; 44 8 3028 3030
126. Chantratita N.; Meumann E.; Thanwisai A.; et al. Loop-mediated isothermal amplification method targeting the TTS1 gene cluster for detection of Burkholderia pseudomallei and diagnosis of melioidosis. J Clin Microbiol: 2008; 46 2 568 573
127. Wuthiekanun V.; Desakorn V.; Wongsuvan G.; et al. Rapid immunofluorescence microscopy for diagnosis of melioidosis. Clin Diagn Lab Immunol: 2005; 12 4 555 556
128. Houghton R. L.; Reed D. E.; Hubbard M. A.; et al. Development of a prototype lateral flow immunoassay (LFI) for the rapid diagnosis of melioidosis. PLoS Negl Trop Dis: 2014; 8 3 e2727
129. Dance D. Treatment and prophylaxis of melioidosis. Int J Antimicrob Agents: 2014; 43 4 310 318
130. Lipsitz R.; Garges S.; Aurigemma R.; et al. Workshop on treatment of and postexposure prophylaxis for Burkholderia pseudomallei and B. mallei Infection, 2010. Emerg Infect Dis: 2012; 18 12 e2
131. Peacock S. J.; Schweizer H. P.; Dance D. A.; et al. Management of accidental laboratory exposure to Burkholderia pseudomallei and B. mallei. Emerg Infect Dis: 2008; 14 7 e2
132. White N. J.; Dance D. A.; Chaowagul W.; Wattanagoon Y.; Wuthiekanun V.; Pitakwatchara N. Halving of mortality of severe melioidosis by ceftazidime. Lancet: 1989; 2 8665 697 701
133. Simpson A. J.; Suputtamongkol Y.; Smith M. D.; et al. Comparison of imipenem and ceftazidime as therapy for severe melioidosis. Clin Infect Dis: 1999; 29 2 381 387
134. Smith M. D.; Wuthiekanun V.; Walsh A. L.; White N. J. Susceptibility of Pseudomonas pseudomallei to some newer beta-lactam antibiotics and antibiotic combinations using time-kill studies. J Antimicrob Chemother: 1994; 33 1 145 149
135. Smith M. D.; Wuthiekanun V.; Walsh A. L.; White N. J. In-vitro activity of carbapenem antibiotics against beta-lactam susceptible and resistant strains of Burkholderia pseudomallei. J Antimicrob Chemother: 1996; 37 3 611 615
136. Cheng A. C.; Fisher D. A.; Anstey N. M.; Stephens D. P.; Jacups S. P.; Currie B. J. Outcomes of patients with melioidosis treated with meropenem. Antimicrob Agents Chemother: 2004; 48 5 1763 1765
137. Huffam S.; Jacups S. P.; Kittler P.; Currie B. J. Out of hospital treatment of patients with melioidosis using ceftazidime in 24-h elastomeric infusors, via peripherally inserted central catheters. Trop Med Int Health: 2004; 9 6 715 717
138. Chierakul W.; Anunnatsiri S.; Short J. M.; et al. Two randomized controlled trials of ceftazidime alone versus ceftazidime in combination with trimethoprim-sulfamethoxazole for the treatment of severe melioidosis. Clin Infect Dis: 2005; 41 8 1105 1113
139. Chierakul W.; Anunnatsiri S.; Chaowagul W.; Peacock S. J.; Chetchotisakd P.; Day N. P. Addition of trimethoprim-sulfamethoxazole to ceftazidime during parenteral treatment of melioidosis is not associated with a long-term outcome benefit. Clin Infect Dis: 2007; 45 4 521 523
140. Wuthiekanun V.; Amornchai P.; Saiprom N.; et al. Survey of antimicrobial resistance in clinical Burkholderia pseudomallei isolates over two decades in Northeast Thailand. Antimicrob Agents Chemother: 2011; 55 11 5388 5391
141. Chantratita N.; Rholl D. A.; Sim B.; et al. Antimicrobial resistance to ceftazidime involving loss of penicillin-binding protein 3 in Burkholderia pseudomallei. Proc Natl Acad Sci U S A: 2011; 108 41 17165 17170
142. Sarovich D. S.; Price E. P.; Von Schulze A. T.; et al. Characterization of ceftazidime resistance mechanisms in clinical isolates of Burkholderia pseudomallei from Australia. PLoS ONE: 2012; 7 2 e30789
143. Crowe A.; McMahon N.; Currie B. J.; Baird R. W. Current antimicrobial susceptibility of first-episode melioidosis Burkholderia pseudomallei isolates from the Northern Territory, Australia. Int J Antimicrob Agents: 2014; 44 2 160 162
144. Chetchotisakd P.; Chierakul W.; Chaowagul W.; et al. Trimethoprim-sulfamethoxazole versus trimethoprim-sulfamethoxazole plus doxycycline as oral eradicative treatment for melioidosis (MERTH): a multicentre, double-blind, non-inferiority, randomised controlled trial. Lancet: 2014; 383 9919 807 814
145. Dance D. A.; Davong V.; Soeng S.; Phetsouvanh R.; Newton P. N.; Turner P. Trimethoprim/sulfamethoxazole resistance in Burkholderia pseudomallei. Int J Antimicrob Agents: 2014; 44 4 368 369
146. Jenney A. W.; Lum G.; Fisher D. A.; Currie B. J. Antibiotic susceptibility of Burkholderia pseudomallei from tropical northern Australia and implications for therapy of melioidosis. Int J Antimicrob Agents: 2001; 17 2 109 113
147. Dance D. A.; Wuthiekanun V.; Chaowagul W.; Suputtamongkol Y.; White N. J. Development of resistance to ceftazidime and co-amoxiclav in Pseudomonas pseudomallei. [letter] J Antimicrob Chemother: 1991; 28 2 321 324
148. Dance D. A.; Wuthiekanun V.; Chaowagul W.; White N. J. The antimicrobial susceptibility of Pseudomonas pseudomallei. Emergence of resistance in vitro and during treatment. J Antimicrob Chemother: 1989; 24 3 295 309
149. Dance D. A.; Wuthiekanun V.; White N. J.; Chaowagul W. Antibiotic resistance in Pseudomonas pseudomallei. Lancet: 1988; 1 8592 994 995
150. Chaowagul W.; Simpson A. J.; Suputtamongkol Y.; Smith M. D.; Angus B. J.; White N. J. A comparison of chloramphenicol, trimethoprim-sulfamethoxazole, and doxycycline with doxycycline alone as maintenance therapy for melioidosis. Clin Infect Dis: 1999; 29 2 375 380
151. Cheng A. C.; Chierakul W.; Chaowagul W.; et al. Consensus guidelines for dosing of amoxicillin-clavulanate in melioidosis. Am J Trop Med Hyg: 2008; 78 2 208 209
152. Cheng A. C.; McBryde E. S.; Wuthiekanun V.; et al. Dosing regimens of cotrimoxazole (trimethoprim-sulfamethoxazole) for melioidosis. Antimicrob Agents Chemother: 2009; 53 10 4193 4199
153. Chaowagul W.; Suputtamongkol Y.; Dance D. A.; Rajchanuvong A.; Pattara-arechachai J.; White N. J. Relapse in melioidosis: incidence and risk factors. J Infect Dis: 1993; 168 5 1181 1185
154. Limmathurotsakul D.; Chaowagul W.; Chantratita N.; et al. A simple scoring system to differentiate between relapse and re-infection in patients with recurrent melioidosis. PLoS Negl Trop Dis: 2008; 2 10 e327
155. Lumbiganon P.; Chotechuangnirun N.; Kosalaraksa P.; Teeratakulpisarn J. Localized melioidosis in children in Thailand: treatment and long-term outcome. J Trop Pediatr: 2011; 57 3 185 191
156. Cheng A. C.; West T. E.; Limmathurotsakul D.; Peacock S. J. Strategies to reduce mortality from bacterial sepsis in adults in developing countries. PLoS Med: 2008; 5 8 e175
157. Cheng A. C.; Stephens D. P.; Anstey N. M.; Currie B. J. Adjunctive granulocyte colony-stimulating factor for treatment of septic shock due to melioidosis. Clin Infect Dis: 2004; 38 1 32 37
158. Cheng A. C.; Limmathurotsakul D.; Chierakul W.; et al. A randomized controlled trial of granulocyte colony-stimulating factor for the treatment of severe sepsis due to melioidosis in Thailand. Clin Infect Dis: 2007; 45 3 308 314
159. Harris P.; Engler C.; Norton R. Comparative in vitro susceptibility of Burkholderia pseudomallei to doripenem, ertapenem, tigecycline and moxifloxacin. Int J Antimicrob Agents: 2011; 37 6 547 549
160. Estes D. M.; Dow S. W.; Schweizer H. P.; Torres A. G. Present and future therapeutic strategies for melioidosis and glanders. Expert Rev Anti Infect Ther: 2010; 8 3 325 338
161. Sarkar-Tyson M.; Atkins H. S. Antimicrobials for bacterial bioterrorism agents. Future Microbiol: 2011; 6 6 667 676
162. Schweizer H. P. When it comes to drug discovery not all Gram-negative bacterial biodefence pathogens are created equal: Burkholderia pseudomallei is different. Microb Biotechnol: 2012; 5 5 581 583
163. Peacock S. J.; Limmathurotsakul D.; Lubell Y.; et al. Melioidosis vaccines: a systematic review and appraisal of the potential to exploit biodefense vaccines for public health purposes. PLoS Negl Trop Dis: 2012; 6 1 1488
164. Choh L. C.; Ong G. H.; Vellasamy K. M.; et al. Burkholderia vaccines: are we moving forward? Front Cell Infect Microbiol: 2013; 3 5